These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21689507)

  • 21. Letter to the Editor re Tapentadol Versus Oxycodone for Opioid-related Adverse Drug Events and Clinical Outcomes After Inpatient Surgery.
    Macintyre PE
    J Pain; 2024 Sep; 25(9):104524. PubMed ID: 39181574
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical efficacy and safety of tapentadol immediate release in the postoperative setting.
    Daniels SE; Golf M
    J Am Podiatr Med Assoc; 2012; 102(2):139-48. PubMed ID: 22461271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Controlled release oxycodone--a new option in the treatment of severe and very severe pain. Review of studies on neuropathic, physical activity-related and postoperative pain].
    Stiehl M
    MMW Fortschr Med; 2004 Aug; 146 Suppl 2():61-9. PubMed ID: 16739361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain.
    Kwong WJ; Ozer-Stillman I; Miller JD; Haber NA; Russell MW; Kavanagh S
    Clin Ther; 2010 Sep; 32(10):1768-81. PubMed ID: 21194601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tapentadol hydrochloride: a centrally acting oral analgesic.
    Wade WE; Spruill WJ
    Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
    Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tapentadol. Acute or chronic pain: no therapeutic advance.
    Prescrire Int; 2014 May; 23(149):121-4. PubMed ID: 24926510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
    Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C
    Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose conversion between tapentadol immediate and extended release for low back pain.
    Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
    Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tapentadol immediate release for the relief of moderate-to-severe acute pain.
    Hartrick CT
    Expert Opin Pharmacother; 2009 Nov; 10(16):2687-96. PubMed ID: 19795998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
    Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
    Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
    Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
    J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.
    Biondi DM; Xiang J; Etropolski M; Moskovitz B
    J Opioid Manag; 2015; 11(5):393-403. PubMed ID: 26535967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of tapentadol for first-line opioid-resistant neuropathic pain in Japan.
    Sugiyama Y; Kataoka T; Tasaki Y; Kondo Y; Sato N; Naiki T; Sakamoto N; Akechi T; Kimura K
    Jpn J Clin Oncol; 2018 Apr; 48(4):362-366. PubMed ID: 29506199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings.
    Alshehri FS
    Drug Des Devel Ther; 2023; 17():851-861. PubMed ID: 36974332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
    Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
    Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tapentadol and nitric oxide synthase systems.
    Bujalska-Zadrożny M; Wolińska R; Gąsińska E; Nagraba Ł
    Behav Pharmacol; 2015 Apr; 26(3):282-8. PubMed ID: 25485639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analgesic update: tapentadol hydrochloride.
    Hersh EV; Golubic S; Moore PA
    Compend Contin Educ Dent; 2010 Oct; 31(8):594-9; quiz 600, 603. PubMed ID: 20960989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies].
    Merker M; Dinges G; Koch T; Kranke P; Morin AM
    Schmerz; 2012 Feb; 26(1):16-26. PubMed ID: 22366930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].
    Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY
    Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.